NVF webinar 13th of December 2023, 16:00 CET, Dr. Rick Greupink and Dr. Manoe Janssen

13th of December at 16:00-17:00 CET

Link: https://teams.microsoft.com/l/meetup-join/19%3ameeting_OGQ5OTAzODYtYzdiYi00MGQ5LTk5NWQtNzBiY2VmMjI0Njkx%40thread.v2/0?context=%7b%22Tid%22%3a%2263ac4101-dd05-4771-bcd6-2e2a5421e5fa%22%2c%22Oid%22%3a%22dcfb3521-fb97-475a-a58f-e03b712cf0f4%22%7d

Speaker 2: Dr. Rick Greupink

Talk 1: Development and application of in vitro, ex vivo and in silico models to assess placental transfer and effects of drugs

Dr. Rick Greupink

Department of Pharmacy, Division of Pharmacology and Toxicology, Radboud university medical center, Nijmegen.

The placenta plays a key role in maintaining a healthy pregnancy. To improve drug safety during gestation, it is relevant to understand to which extent and at which rate drugs are transferred across the placenta. While crossing the placenta, pharmaceuticals may also affect placental function. Pregnant women are not readily enrolled in clinical pharmacology trials, therefore data on drug efficacy and safety during pregnancy are scarce or become available only at a late stage after market introduction of a pharmaceutical. Translational pharmacology studies based on human tissues and cells are becoming increasingly important to fill this knowledge gap. In my talk I will highlight several ex vivo and in vitro models that we use to investigate the placental disposition and effects of small and large molecule pharmaceuticals, as well as how non-clinical pharmacokinetic data may be used in combination with physiology-based pharmacokinetic (PBPK) modeling to better understand clinical pharmacology during pregnancy.

Speaker 2: Dr. Manoe Janssen

Talk 2: Advanced in vitro cell models to study genetic kidney diseases – An in vitro adventure

Dr. Manoe Janssen

Div. of Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, the Netherlands

My research group is embedded in the group of Prof Dr Roos Masereeuw at the division of Pharmacy at Utrecht University. I specialize in the field of genetics and genetic disease, with a focus on genetic kidney diseases and lysosomal storage diseases. We use CRISPR/cas technology to develop new disease models and therapies. It is my ambition to improve the translational value of in vitro models and in this way contribute to the development of new therapies.